Valiant Laboratories

Valiant Laboratories Debt/EBITDA

The Total Debt to EBITDA Ratio of Valiant Laboratories (VALIANTLAB.NS) as of Nov 4, 2026 is 17.30. In the previous year, Total Debt to EBITDA Ratio was 6.11 — a change of 183.27% (higher).

Debt/EBITDA

17.30

YoY

183.27%

Last updated:

Total Debt to EBITDA Ratio of Valiant Laboratories is 2026 17.30 . Total Debt to EBITDA Ratio of Valiant Laboratories was 2025 6.11 . It decreases by 183.27% higher compared to the previous year.

The Valiant Laboratories Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2021
0.01 INR
Jan 1, 2022
1.47 INR
Jan 1, 2023
1.68 INR
Jan 1, 2024
8.31 INR
Jan 1, 2025
6.11 INR
Jan 1, 2026
17.30 INR
The Valiant Laboratories Debt/EBITDA history
YEARDebt/EBITDAYoY
17.30+183.27%
6.11-26.51%
8.31+395.16%
1.68+14.31%
1.47+11,423.05%
0.01—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valiant Laboratories Stock analysis

What does Valiant Laboratories do? Valiant Laboratories Ltd manufactures paracetamol API/bulk drug for pharmaceutical applications, targeting medical conditions such as headache, muscle ache, arthritis, back ache, toothache, cold, and fever. The company operates a single manufacturing facility at Tarapur industrial estate, approximately 150 km from Nhava Sheva Port (JNPT), producing specialty chemicals and pharma intermediates for domestic and international markets. Its subsidiary, VALIANT ADVANCED SCIENCES PRIVATE LIMITED, supports the company's operations in the pharmaceutical sector. The firm's primary revenue comes from selling paracetamol API and specialty chemicals to pharmaceutical companies and distributors globally. Manufacturing focuses on high-demand applications like pain relief and fever treatment, with products distributed across India and abroad. The company leverages its Tarapur facility's proximity to Nhava Sheva Port for efficient export logistics. Valiant Laboratories Ltd serves the pharmaceutical industry by supplying essential active ingredients, particularly paracetamol, which is widely used in over-the-counter medications. The company's manufacturing capabilities for specialty chemicals and pharma intermediates cater to both domestic and international clients seeking reliable API sources. Its single-location production model ensures focused resource allocation for consistent output quality. Valiant Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Valiant Laboratories stock

Total Debt to EBITDA Ratio of Valiant Laboratories is 17.30 in 2026.

Total Debt to EBITDA Ratio of Valiant Laboratories changed from 6.11 to 17.30, representing a 183.27% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Valiant Laboratories since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Valiant Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Valiant Laboratories

All Key Metrics — Valiant Laboratories